GroEL/ES inhibitors as potential antibiotics by Abdeen, Sanofar et al.
GroEL/ES inhibitors as potential antibiotics 
Sanofar Abdeen,a Nilshad Salim,a Najiba Mammadova,a,f Corey Summers,a,g Rochelle 
Frankson,a,h Andrew J. Ambrose,b Gregory G. Anderson,c Peter G. Schultz,d Arthur L. Horwich,e 
Eli Chapman,b and Steven M. Johnsona* 
a Indiana University, School of Medicine, Department of Biochemistry and Molecular Biology, 
635 Barnhill Dr., Indianapolis, IN 46202 
b The University of Arizona, College of Pharmacy, Department of Pharmacology and 
Toxicology, 1703 E. Mabel St., PO Box 210207, Tucson, AZ 85721 
c Indiana University-Purdue University Indianapolis, Department of Biology, 723 W. Michigan 
St., Indianapolis, IN 46202 
d The Scripps Research Institute, Department of Chemistry, 10550 North Torrey Pines Rd., La 
Jolla, CA 92037 
e HHMI, Department of Genetics, Yale School of Medicine, Boyer Center for Molecular 
Medicine, 295 Congress Ave., New Haven, CT 06510 
Present addresses: 
f Department of Genetics, Development and Cell Biology, Iowa State University, 1210 
Molecular Biology Building, Pannel Dr, Ames, IA 50011 
g Department of Kinesiology, Iowa State University, 235 Barbara E. Forker Building, Beach Rd, 
Ames, IA 50011 
h Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, Hansen 
Life Sciences Research Building, 201 S. University Street, West Lafayette, IN 47907 
*Correspondence: johnstm@iu.edu, Tel: 317-274-2458, Fax: 317-274-4686
KEYWORDS. GroEL, GroES, HSP60, HSP10, molecular chaperone, chaperonin, proteostasis, 
small molecule inhibitors, ESKAPE pathogens, antibiotics. 
_________________________________________________________________________________
 
This is the author's manuscript of the article published in final edited form as: 
Abdeen, S., Salim, N., Mammadova, N., Summers, C. M., Frankson, R., Ambrose, A. J., … Johnson, S. M. (2016). 
GroEL/ES inhibitors as potential antibiotics. Bioorganic & Medicinal Chemistry Letters, 26(13), 3127–3134. 
https://doi.org/10.1016/j.bmcl.2016.04.089
2 
 
Abstract: 
We recently reported results from a high-throughput screening effort that identified 235 
inhibitors of the Escherichia coli GroEL/ES chaperonin system [Johnson et al., 2014].  As the 
GroEL/ES chaperonin system is essential for growth under all conditions, we reasoned that 
targeting GroEL/ES with small molecule inhibitors could be a viable antibacterial strategy.  
Extending from our initial screen, we report here the antibacterial activities of 22 GroEL/ES 
inhibitors against a panel of Gram-positive and Gram-negative bacteria, including E. coli, 
Bacillus subtilis, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter cloacae.  GroEL/ES 
inhibitors were more effective at blocking the proliferation of Gram-positive bacteria, in 
particular S. aureus, where lead compounds exhibited antibiotic effects from the low-M to mid-
nM range.  While several compounds inhibited the human HSP60/10 refolding cycle, some were 
able to selectively target the bacterial GroEL/ES system.  Despite inhibiting HSP60/10, many 
compounds exhibited low to no cytotoxicity against human liver and kidney cell lines.  Two lead 
candidates emerged from the panel, compounds 8 and 18, that exhibit >50-fold selectivity for 
inhibiting S. aureus growth compared to liver or kidney cell cytotoxicity.  Compounds 8 and 18 
inhibited drug-sensitive and methicillin-resistant S. aureus strains with potencies comparable to 
vancomycin, daptomycin, and streptomycin, and are promising candidates to explore for 
validating the GroEL/ES chaperonin system as a viable antibiotic target.   
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The number of lives saved by antibiotics is a hallmark of the success of this class of 
drugs.  However, resistant bacterial strains have been identified for every class of antibiotic, 
usually within a few years of general therapeutic use.1-3  The threat of antibiotic resistance is 
epitomized by the emergence of six multi-drug resistant bacteria referred to as the ESKAPE 
pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa, and Enterobacter species.4-8  The Center for Disease 
Control (CDC) Antibiotic Resistance Threat Report lists these bacteria as serious threats (level 4 
out of 5) requiring prompt and sustained action.9  Most alarming is that antibiotic resistance has 
mounted to the point where therapeutics are severely limited or ineffective for once easily treated 
infections.  For example, ~10,000 people per year are estimated to die from methicillin-resistant 
S. aureus (MRSA) infections in the United States.10  Moreover, the CDC estimates the direct 
medical cost of treating antibiotic resistant bacterial infections in the US is more than $20 billion 
per year.9  Clearly, the rise of resistant bacterial strains requires enhanced research efforts to 
ensure an ongoing antibiotic pipeline.   
Current antibiotics primarily function by blocking cell wall construction, structure and 
function of the cell membrane, protein synthesis, DNA structure and function, or folic acid 
synthesis.11  Recently developed therapeutics for infections caused by drug-resistant bacteria 
include the injectable carbapenem beta-lactam, doripenem, which targets penicillin-binding 
proteins and inhibits cell wall synthesis;12 the cyclic lipopeptide, daptomycin, which inserts into 
the bacterial membrane and leads to pore formation;13 quinupristin/dalfopristin, which bind to 
two different sites on the 50S ribosomal subunit and interfere with protein synthesis;14 the 
oxazolidinone, linezolid, which also binds the 50S ribosomal subunit;15 the tetracycline 
derivative, tigecycline, which targets protein synthesis via the 30S ribosomal subunit;16 and the 
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lipoglycopeptide, dalbavancin, which has the same mode of action as vancomycin, binding to the 
D-Ala-D-Ala motif in the cell wall.17  As these examples illustrate, most new antibiotics are 
derivatives of existing drugs that also target the aforementioned pathways.  Unfortunately, 
bacterial resistance to these drugs is quick to develop.  These data argue for the continued pursuit 
of antibiotics with entirely new modes of action, which may better avoid mechanisms of 
resistance and have longer effective life times. 
 
Figure 1. General protocol for chaperonin-mediated biochemical assays. Compounds (I) are 
added at point A to a solution containing GroEL (or HSP60) with bound substrate protein (e.g. 
malate dehydrogenase, MDH).  Addition of GroES (or HSP10) and ATP initiates the refolding 
cycle, which is quenched with EDTA after a 60 minute incubation. Substrates (R) for the 
refolded reporter enzyme are added and after another 30-60 minute incubation (until the DMSO 
control wells have reached ~90% consumption of NADH), absorbance is measured to evaluate 
the amount of refolded enzyme present, and by association the extent of chaperonin inhibition.  
Alternatively, addition of compounds at point B enables determination of off-target inhibition of 
the reporter enzyme (i.e. native MDH enzyme activity).  Chaperonin-mediated ATP hydrolysis is 
also evaluated using a malachite green assay.  Biochemical assays employing Rhodanese (Rho) 
are performed similarly (refer to the Supporting Information for detailed protocols).  
An attractive strategy for the development of novel antibiotics is to target bacterial 
protein homeostasis (proteostasis) mechanisms, in particular molecular chaperones.  Molecular 
chaperones are a specialized class of proteins that help other proteins to properly fold to their 
native states.  Among the molecular chaperones in E. coli, the GroEL/ES chaperonin system is 
the only one essential for growth under all conditions.18, 19   GroEL is a central processing 
5 
 
machine that maintains the structural and functional integrity of many other proteins (Figure 1); 
for a review, see references 19 and 20.19-22 Thus, targeting this one functional node results in a 
cascading effect that leads to the dysfunction of numerous key cellular pathways, which is lethal 
to bacteria.18  Because no other drugs function by targeting chaperonin systems, this strategy 
should be effective against bacteria that are resistant to current antibiotics.   
  The central tenet of this antibiotic strategy raises the question of whether bacterial 
GroEL/ES can be targeted specifically without interfering with the metazoan counterpart in the 
mitochondria, HSP60/10, whose partial deficiency in humans leads to disease.23  Human HSP60 
shares 48% sequence identity with E. coli GroEL, and thus there is the possibility of inhibitor 
cross-talk between the two chaperonins.  However, structural and functional differences between 
the two systems suggest that it should be possible to develop inhibitors that selectively target 
bacterial GroEL/ES over human HSP60/10.  GroEL is a homo-tetradecameric protein consisting 
of two, seven-membered rings that stack back-to-back.24-26  Through a series of events driven by 
ATP binding and hydrolysis, unfolded substrate proteins are bound within the central cavity of 
one GroEL ring and encapsulated by the heptameric GroES co-chaperonin lid structure, 
triggering protein folding in a sequestered chamber.25-31  GroEL/ES works as an allosterically-
controlled, double-ring system, which is regulated through positive intra-ring ATP-binding and 
negative inter-ring binding.  In contrast, studies have indicated that human HSP60/10 operates as 
a single-ring species, through at least part of the cycle, removing many of the intermediate states 
associated with the GroEL/ES refolding cycle.32-34  Thus, it should be possible to develop 
inhibitors that selectively target the double-ring GroEL/ES cycle with its additional allosteric 
signals and conformational intermediates.  Furthermore, HSP60/10 is in the mitochondrial 
matrix, which is often protected from small molecule penetration; thus, even if compounds are 
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found that inhibit HSP60/10 in biochemical assays, they may not display cytotoxicity if they 
failed to reach the mitochondrial matrix.   
We previously developed a series of compounds that bind to the ATP sites of E. coli 
GroEL and inhibit the chaperonin refolding cycle.35, 36  We also conducted a high-throughput 
screen to discover inhibitors of the E. coli GroEL/ES chaperonin system that target sites other 
than the ATP pockets, as we had concerns that ATP-competitive inhibitors may have off-target 
effects against other ATP-dependent proteins in cells.37  We chose the E. coli GroEL/ES 
homolog for screening because it is the best characterized chaperonin and has been a model 
system for studying this class of proteins.30, 31, 38-40  It shares high homology with GroEL/ES 
systems from other bacteria, with 56-97% identical amino acids for GroEL and 44-94% identical 
amino acids for GroES (refer to Table S1 in the Supporting Information).  Thus, E. coli 
GroEL/ES serves as an excellent surrogate to discover chaperonin inhibitors to treat bacterial 
infections.  The assays we developed analyzed the full refolding cycle and used the substrate 
reporter enzymes -arylsulfotransferase IV (AST-IV) and malate dehydrogenase (MDH), which 
require GroEL, GroES, and ATP in order to return to their native, active states (refer to Figure 1 
for a general overview of the assay protocols).  From ~700,000 molecules, our high-throughput 
screening narrowed the number of GroEL/ES inhibitors to 235.  We investigated a subset of 
these hits in greater detail to identify IC50 values for inhibiting GroEL/ES-mediated substrate 
refolding and ATPase activity.  While only a few compounds inhibited GroEL/ES-mediated 
ATPase activity, most were potent inhibitors of the refolding cycle and exhibited minimal to no 
off-target effects against the reporter enzyme.37   
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Figure 2.  Structures of the 22 compounds under evaluation.  For ease of comparison, compound 
numbering from 1-36 was maintained as presented in our previous high-throughput screening 
study.37  Compounds 2-4, 6, 7, 12, 13, 16, 17, 21, 22, 26, 30, and 36 were omitted from 
evaluation as they were either not commercially available, or purchased compounds were not 
readily identified by LC-MS and/or did not have acceptable purities confirmed by HPLC.   
 
Extending from our high-throughput screening studies, we have been investigating the 
antibiotic potential of 22 of our initial GroEL/ES inhibitor hits (Figure 2).  We first tested the 
GroEL/ES inhibitors in two additional biochemical counter-screens to further support that they 
are acting “on-target” and are not simply artifacts or false-positives.  The first counter-screen 
evaluates for inhibition of GroEL/ES-mediated refolding of a third stringent substrate, 
Rhodanese (Rho).  The second counter-screen evaluates for inhibition of the native Rho 
enzymatic reporter reaction.  Detailed protocols for these two assays are presented in the 
Supporting Information).41-44  For most of the compounds, we found a direct correlation between 
1
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inhibition of both the GroEL/ES-mediated dMDH and dRho refolding reactions (Table 1 and 
Figure 3A).  While some compounds inhibited either the native MDH or Rho reporter reactions, 
only compound 10 inhibited in both counter-screens, and only to a minor extent against native 
MDH (Table 1 and Figure 3B).  Thus, we are confident that compounds are on-target inhibitors 
of dMDH and dRho refolding.  We next evaluated the 22 compounds for their antibiotic effects 
on E. coli cells.  A general bacterial proliferation assay (see the Supporting Information for a 
detailed protocol) was employed in liquid media using DH5E. coli cells as the initial test strain 
(EC50 values are summarized in Table 2 and graphically in Figure 4A).  Unfortunately, no 
significant inhibition of bacterial growth was observed for any of the compounds up to 100 M.  
Reasoning this might be due to efflux of the molecules, we tested against an MC4100 ΔacrB E. 
coli strain, which has one of the central components of the AcrA/AcrB/TolC efflux pump 
removed.45, 46  Compounds 8 and 18 were the most potent inhibitors of this efflux-compromised 
E. coli strain (EC50 = 2.3 and 21 M, respectively), with the remainder of the compounds being 
inactive. 
Table 1. Biochemical IC50 results for E. coli GroEL/ES inhibitors.  Statistical analyses (two-
tailed t-tests) were performed for compound log(IC50) values determined from the GroEL/ES-
dRho and GroEL/ES-dMDH refolding assays.  Compounds for which there is a statistically 
significant difference between inhibition results have been marked with a “” between the two 
assay results being compared (p < 0.05).  P-values could not be calculated for compounds 
marked with a “#”as one IC50 is greater than the maximum compound concentration tested.  For 
most compounds, IC50 values are not statistically different (17/22 compounds), suggesting they 
are “on-target” for inhibiting the refolding of the dRho and dMDH substrates.  IC50 correlations 
are represented graphically in Figure 3.   
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Figure 3.  A. Compounds inhibit nearly equipotently in the E. coli GroEL/ES-dMDH and the 
GroEL/ES-dRho refolding assays.  Data plotted in the grey zones represent results beyond the 
assay detection limits (i.e. >100 M for the dMDH refolding assay, and >250 M for the dRho 
refolding assay).  Compounds indicated by the white squares are those with statistically 
significant differences between their IC50 values (p < 0.05).  B. While some compounds inhibit 
either native MDH or Rho individually, only compound 10 inhibits in both counter-screens, and 
only to a minor extent against native MDH.  Data plotted in the grey zones represent results 
#
1 
5
8
9
10     
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23
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27 
28     
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32 
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35 #
IC50 = Inhibitor Concentration resulting in 50% reduction of biochemical activity
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>62.5
>62.5
>62.5
>62.5
>62.5
>62.5
>62.5
>62.5
>62.5
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>62.5
>62.5
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>62.5
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1.4
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3.6
6.5
4.7
2.6
24
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25
79
10
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>100
>100
30
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1.4
1.4
0.47
0.83
2.5
1.7
6.8
3.0
22
2.4
2.3
2.6
9.6
0.89
28
18
11
8.1
>100
2.1
>100
1.4
12
5.3
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>100
14
>100
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0.25
12
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GroEL/ES-dMDH 
Refolding
GroEL/ES-dMDH 
ATPase
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Refolding
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Reporter Activity
Native Rho 
Reporter Activity
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beyond the assay detection limits (i.e. >62.5 M for the native MDH enzymatic reporter assay, 
and >100 M for the native Rho enzymatic reporter assay).   
That many of the most potent GroEL/ES biochemical inhibitors were ineffective against 
the MC4100 ΔacrB E. coli cells could be due to the presence of other efflux pumps that were 
still functional, as it is known that E. coli contains several classes of efflux pumps.47-50  However, 
another possibility is that the molecules were not able to traverse the highly impermeable 
lipopolysaccharide (LPS) outer membrane characteristic of Gram-negative bacteria.  To probe 
this, we tested the compounds against a mutant SM101 lpxA2 E. coli strain, which has a 
temperature sensitive LpxA allele leading to compromised LPS biosynthesis at non-permissive 
temperatures, and consequently a greater permeability to molecules.51, 52  We found that 10 
compounds inhibited the growth of this E. coli strain, with compounds 8 and 18 still proving to 
be the most effective (EC50 values of 0.33 and 3.3 M, respectively).  These results were further 
supported by the ability of many compounds to inhibit the growth of a Gram-positive bacterium, 
Bacillus subtilis (Table 2 and Figure 4B), which does not contain an LPS outer membrane.  That 
more compounds failed to inhibit either the SM101 lpxA2 E. coli or B. subtilis bacteria is 
putatively because of the presence of efflux pumps that were still intact for these strains, and/or 
the continued impermeability of compounds across the cell membranes. 
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Table 2.  E. coli and B. subtilis bacterial proliferation EC50 results for GroEL/ES inhibitors. 
 
     
Figure 4.  A. Inhibitors of the E. coli GroEL/ES-dMDH refolding cycle are inactive against 
parent E. coli bacteria; however, several exhibit antibacterial effects against mutant E. coli 
strains with compromised efflux pumps (MC4100 ΔacrB) and lipopolysaccharide (LPS) outer 
membranes (SM101 lpxA2).  B. Parent B. subtilis, E. faecium, and S. aureus Gram-positive 
bacteria are more susceptible to the antibiotic effects of GroEL/ES inhibitors.  Compound 8 
#
1
5
8
9
10   
11
14
15
18
19
20    
23
24
25
27
28
29   
31
32
33
34   
35
EC50 = Effective Concentration of compound resulting in 50% reduction of bacterial 
proliferation
Bacterial Proliferation EC50 Values (M)
SM101 
E. coli
DH5
E. coli 
MC4100  AcrB    
E. coli 
B. subtilis
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
92
2.3
>100
>100
>100
>100
>100
21
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
27
0.33
76
>100
48
>100
84
3.3
72
>100
7.6
>100
>100
>100
>100
>100
>100
>100
19
13
>100
68
>100
25
>100
>100
25
0.10
>100
>100
>100
>100
>100
0.47
16
2.8
>100
>100
>100
>100
43
>100
83
0.1 1 10 100
0.1
1
10
100
GroEL/ES-dMDH Refolding IC50 ( M )
A.
SM101 lpxA2MC4100 acrB
8
18
0.1 1 10 100
0.1
1
10
100
GroEL/ES-dMDH Refolding IC50 ( M )
B.
B. subtilis E. faecium S. aureus
8
18
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potently inhibits the growth of all three strains, while compound 18 is potent against B. subtilis 
and S. aureus, but inactive against E. faecium.  Data plotted in the grey zones represent results 
beyond the assay detection limits (i.e. >100 M).   
 
While E. coli and B. subtilis were good model systems for initial proof-of-principle 
studies, we wanted to elucidate the antibiotic potential of our GroEL/ES inhibitors against a 
panel of more clinically relevant bacteria, in particular the ESKAPE pathogens.  We adapted the 
general bacterial proliferation assay to test molecules against E. faecium, S. aureus (plus an 
MRSA strain), K. pneumoniae, A. baumannii, P. aeruginosa, and E. cloacae (see the Supporting 
Information for detailed protocols).  A summary of the EC50 values for compounds against these 
bacteria is presented in Table 3 (and graphically in Figure 4B), with a comparison against 
several common antibiotics.  As four of the ESKAPE pathogens are Gram-negative (K. 
pneumoniae, A. baumannii, P. aeruginosa, and E. cloacae), it is not surprising that the 
GroEL/ES inhibitors were largely ineffective against them.  The remaining two ESKAPE 
pathogens, E. faecium and S. aureus, are Gram-positive bacteria.  Compound 8 was very potent 
at inhibiting E. faecium growth (EC50= 0.15 M), and compound 32 was moderately potent 
(EC50 = 15 M).  Somewhat surprisingly, compound 18, which emerged as a lead inhibitor 
against the E. coli and B. subtilis cells, was inactive against E. faecium.  The remaining 
compounds were ineffective against E. faecium, which again supports the notion that the 
presence of an LPS membrane is not the sole determinant leading to compound inactivity.  While 
compounds 8 and 18 emerged as the lead inhibitors of S. aureus growth (EC50 = 0.20 M and 1.8 
M, respectively), four other compounds were also moderately effective with EC50 values 
between 10-50 M (5, 11, 19, and 28).  To determine if they were bactericidal or bacteriostatic, 
we analyzed lead compounds 8 and 18 against the methicillin susceptible S. aureus strain (ATCC 
25923) and found that both were acting as bactericidal inhibitors (refer to Figure S1 in the 
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Supporting Information).  We further tested compounds against an MRSA strain (ATCC #BAA-
44: HPV107 strain, SCCmec Type I, Iberian PFGE Type) and found a correlation with the 
methicillin susceptible S. aureus strain (Table 3).   
Table 3.  EC50 results for GroEL/ES inhibitors against the ESKAPE pathogens. 
 
 
While we have identified numerous inhibitors of GroEL/ES biochemical function, several 
of which we now know inhibit the growth of pathogenic bacteria (in particular S. aureus and 
MRSA), there remained the possibility that these compounds could be toxic to host cells owing 
to targeting of HSP60/10.  To account for this possibility, in vitro counter-screens were carried 
out in analogous chaperonin-mediated dMDH refolding and ATPase biochemical assays 
employing HSP60/10 (Table 4).  As indicated in Figure 5A, there was a correlation observed for 
#
1
5
8
9
10       
11
14
15
18
19
20       
23
24
25
27
28
29       
31
32
33
34       
35
Ampicillin
Minocycline
Rifampicin
Chloramphenicol
Kanamycin
Streptomycin
Vancomycin
Daptomycin
EC50 = Effective Concentration of compound resulting in 50% reduction of bacterial proliferation
Bacterial Proliferation EC50 Values (M)
A. baumannii P. aeruginosa E. cloacaeE. faecium S. aureus K. pneumoniaeMRSA
>100
90
0.15
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
15
>100
>100
>100
0.63
<0.05
1.2
2.1
>100
50
0.30
33
>100
14
0.20
>100
82
23
>100
>100
1.8
13
>100
>100
>100
>100
80
45
>100
>100
84
>100
>100
>100
0.059
<0.05
<0.05
2.2
8.2
3.6
0.20
5.7
>100
9.1
0.13
>100
>100
40
94
>100
1.3
1.5
21
>100
61
>100
>100
74
15
56
54
>100
>100
>100
76
0.35
0.15
2.3
>100
>100
0.17
5.7
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
95
>100
>100
>100
>100
89
0.70
5.4
1.4
45
3.4
>100
>100
>100
58
30
>100
>100
>100
>100
81
>100
>100
>100
>100
>100
>100
>100
>100
>100
32
>100
>100
>100
>100
2.5
<0.05
0.47
65
16
>100
17
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
85
>100
>100
>100
>100
>100
27
2.4
5.2
16
25
2.9
74
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
1.5
6.2
2.2
37
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inhibiting both E. coli GroEL/ES and human HSP60/10; however, compounds were generally 
more potent at inhibiting E. coli GroEL/ES.  Notably, compounds 1 and 18 displayed 12-fold and 
>17-fold selectivities, respectively, for inhibiting E. coli GroEL/ES over human HSP60/10.  
Unfortunately, the other lead inhibitor against S. aureus and MRSA bacteria, compound 8, was 
only 4-fold selective.  Thus, we were concerned about the cytotoxicity against human cells of 8 
and other compounds that inhibited the HSP60/10 refolding cycle.   
Table 4.  Human HSP60/10 biochemical IC50 and liver and kidney cytotoxicity EC50 results for 
the GroEL/ES inhibitors.  Statistical analyses (two-tailed t-tests) were performed for compound 
log(IC50) values determined from the GroEL/ES-dMDH and HSP60/10-dMDH refolding assays.  
Compounds for which there is a statistically significant difference between inhibition results 
have been marked with a “” between the two assay results being compared (p < 0.05).  P-values 
could not be calculated for compounds marked with a “#”as one IC50 is greater than the 
maximum compound concentration tested.  IC50 correlations are represented graphically in 
Figure 5A. 
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5 
8 
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11 
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13
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15
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1.8
38
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5.5
1.6
3.3
5.2
7.4
10
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16
2.8
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HSP60/10-dMDH 
Refolding
GroEL/ES-dMDH 
Refolding
HSP60/10-dMDH 
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7.5
0.69
29
16
89
4.9
1.4
0.93
0.80
1.2
3.0
2.7
5.7
4.8
5.4
4.7
3.6
6.5
4.7
2.6
24
31
42
>100
24
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Figure 5.  A. Compounds inhibit both E. coli GroEL/ES and human HSP60/10 chaperonin 
systems, but are generally more selective for the bacterial homolog.  Compound 18 is inactive 
against human HSP60/10, whereas compound 8 exhibits low selectivity for GroEL/ES.  B. Even 
though compounds can inhibit HSP60/10 biochemical function, many exhibit low or no 
cytotoxicity to human liver and kidney cells.  Compound 18 exhibits no cytotoxicity, whereas 
compound 8 exhibits moderate or low toxicity.  Data plotted in the grey zones represent results 
beyond the assay detection limits (i.e. >100 M). 
To gauge for potential cytotoxicity of chaperonin inhibitors to host tissues, we next 
evaluated compounds in viability assays using cultured human liver (THLE-3) and kidney (HEK 
293) cells.  These two stable cell lines were chosen because they are derived from the two main 
organs responsible for drug metabolism and excretion.  An Alamar Blue-based cell viability 
assay was employed to probe for cytotoxicity.53, 54  We observed that inhibition of HSP60/10 
biochemical activity did not directly translate into cell toxicity and that many compounds were 
only moderately toxic or non-toxic to both cell lines (Table 4 and Figure 5B).  This could be 
due to the fact that the inner mitochondrial membrane is highly impermeable to compounds, and 
thus inhibitors may not be able to penetrate to the mitochondrial matrix to reach HSP60/10.  
Compounds 8 and 18 were the most potent inhibitors of S. aureus proliferation, with the greatest 
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therapeutic windows compared to liver and kidney cell cytotoxicity (Figure 6).  In particular, 
compound 8, which exhibits an EC50 of 0.20 M against S. aureus proliferation, has a 
therapeutic window of 60-fold with THLE-3 cells, and 390-fold with HEK 293 cells.  Compound 
18, which exhibits an EC50 of 1.8 M against S. aureus proliferation, is non-toxic to the liver and 
kidney cells up to the maximum concentrations tested (EC50 >100 M; therapeutic window >55-
fold). 
 
Figure 6.  Compounds 8 and 18 are potent antibacterials against S. aureus & MRSA, with 
moderate/low to no toxicity to human liver and kidney cells.  Results for Vancomycin (Van), 
Daptomycin (Dap), and Streptomycin (Strep) are shown for comparisson. Arrows () indicate 
EC50 results are >100 M (the maximum concentrations tested). 
In conclusion, we have investigated a subset of our previously identified inhibitors of the 
E. coli GroEL/ES chaperonin system for their antibiotic potential against a panel of bacteria 
including E. coli (3 strains), B. subtilis, E. faecium, S. aureus (including an MRSA strain), K. 
pneumoniae, A. baumannii, P. aeruginosa, and E. cloacae.  The reported GroEL/ES inhibitors 
were largely ineffective at preventing the proliferation of the Gram-negative bacteria.  While 
bacterial LPS outer membranes certainly play a significant role in preventing inhibitors from 
8 18 Van Dap Strep
0.1
1
10
100
S. aureus
MRSA
Liver (THLE-3)
Kidney  (HEK 293)
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penetrating these bacteria, our studies with the mutant MC4100 ΔacrB E. coli strain indicate that 
drug efflux is another contributing factor to inhibitor inactivation.  Compounds 8 and 18 
emerged as the lead candidate GroEL/ES inhibitors that exhibit >50-fold selectivity for blocking 
the growth of S. aureus bacteria versus human liver and kidney cytotoxicities.  Their antibiotic 
efficacies against S. aureus are comparable to vancomycin, daptomycin, and streptomycin 
(Figure 6).  Furthermore, they are effective against the MRSA strain evaluated here.  We are 
pursuing further medicinal chemistry derivatization of these GroEL/ES inhibitors to develop lead 
analogs with more potent antibiotic effects against S. aureus (and ideally other bacteria) that 
remain non-toxic to mammalian cells.  Since these inhibitors were discovered in a targeted 
GroEL/ES screen, we consider this the putative target, but we cannot rule out the possibility of 
off-target effects contributing to antibacterial potency.  We are designing experiments to 
delineate the mechanism of action at the protein level and the mode of action at the whole cell 
level for these GroEL/ES inhibitors.  The results presented here are encouraging, leading us to 
believe we can selectively target bacterial GroEL/ES chaperonin systems as an antibiotic 
strategy. 
 
Supporting Information:   
Supporting information associated with this article can be found in the online version, which 
includes tabulations of log(IC50) and log(EC50) results with standard deviations; experimental 
protocols for biochemical and cell-based assays; synthetic protocols and characterization data for 
compounds 10, 15, 23, 24, and 25; and HPLC purity and MS characterization of test compounds. 
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S3 
Table S1: Amino acid sequence conservation for ESKAPE pathogen and human chaperonins and co-
chaperonins.  Values represent % identical amino conservation compared to E. coli GroEL and GroES. 
 
 
 
GroEL (HSP60) GroES (HSP10)
E. coli 100% 100%
E. faecium 56.5% 47.3%
S. aureus 57.1% 44.1%
K. pneumoniae 96.5% 93.8%
A. baumannii 75.5% 62.1%
P. aeruginosa 80.0% 60.4%
E. cloacae 96.3% 93.8%
H. sapiens 48.0% 35.4%
S4 
Table S2: Biochemical inhibition results for E. coli GroEL/ES inhibitors.  Statistical analyses (two-
tailed t-tests) were performed for compound log(IC50) values determined from the GroEL/ES-dRho and 
GroEL/ES-dMDH refolding assays.  Compounds for which there is a statistically significant difference 
between inhibition results have been marked with a “” between the two assay results being compared 
(p < 0.05).  P-values could not be calculated for compounds marked with a “#”as one IC50 is greater than 
the maximum compound concentration tested.  For most compounds, IC50 values are not statistically 
different (17/22 compounds).  IC50 correlations are represented graphically in Figure 3 in the main text.   
 
  
#
1 >2 >1.8 1.47 ± 0.35  0.88 ± 0.61 2.08 ± 0.07
5 1.16 ± 0.28 >1.8 -0.23 ± 0.12 -0.16 ± 0.35 >2.4
8 >2 0.85 ± 0.33 0.16 ± 0.06 0.15 ± 0.20 >2.4
9 >2 >1.8 0.14 ± 0.11 -0.03 ± 0.27 1.90 ± 0.07
10 -0.60 ± 0.03  1.73 ± 0.08  -0.33 ± 0.19  -0.10 ± 0.21  2.24 ± 0.05
11 1.06 ± 0.17 >1.8 -0.08 ± 0.04 0.09 ± 0.50 2.34 ± 0.13
14 0.40 ± 0.32 >1.8 0.40 ± 0.31 0.48 ± 0.57 >2.4
15 1.36 ± 0.12 >1.8 0.24 ± 0.14 0.44 ± 0.52 >2.4
18 >2 >1.8 0.83 ± 0.31 0.76 ± 0.29 >2.4
19 0.91 ± 0.30 >1.8 0.48 ± 0.22 0.68 ± 0.48 >2.4
20 >2  >1.8  1.34 ± 0.10  0.73 ± 0.26  >2.4
23 0.31 ± 0.17 >1.8 0.38 ± 0.11 0.67 ± 0.82 >2.4
24 >2 >1.8 0.37 ± 0.12 0.56 ± 0.45 >2.4
25 0.16 ± 0.14 >1.8 0.41 ± 0.16 0.81 ± 0.46 >2.4
27 1.09 ± 0.07 >1.8 0.98 ± 0.09  0.67 ± 0.30 >2.4
28 0.73 ± 0.54  >1.8  -0.05 ± 0.15  0.42 ± 0.62  >2.4
29 >2 >1.8 1.44 ± 0.13 1.38 ± 0.07 2.27 ± 0.06
31 1.72 ± 0.21 >1.8 1.27 ± 0.14 1.49 ± 0.61 >2.4
32 1.00 ± 0.55 >1.8 1.04 ± 0.32  1.62 ± 0.16 2.34 ± 0.04
33 >2 >1.8 >2.4 >2 >2.4
34 >2 >1.8 1.40 ± 0.10 1.38 ± 0.37 >2.4
35 >2 >1.8 1.90 ± 0.34 # >2 2.03 ± 0.04
IC50 = Inhibitor Concentration resulting in 50% reduction of biochemical activity
Native Rho 
Reporter Activity
Biochemical Assay log(IC50 /M) Values ± SD
GroEL/ES-dMDH 
Refolding
GroEL/ES-dMDH 
ATPase
GroEL/ES-dRho 
Refolding
Native MDH 
Reporter Activity
S5 
Table S3: E. coli and B. subtilis bacterial proliferation inhibition results for GroEL/ES inhibitors.  
Results are presented as log(EC50 /M) values ± their standard deviations (SD).   
 
 
  
#
1 >2 >2 >2 >2
5 >2 1.96 ± 0.10 1.42 ± 0.16 1.40 ± 0.23
8 >2 0.37 ± 0.38 -0.48 ± 0.78 -0.99 ± 0.25
9 >2 >2 1.88 ± 0.12 >2
10 >2 >2  >2  >2
11 >2 >2 1.68 ± 0.31 >2
14 >2 >2 >2 >2
15 >2 >2 1.92 ± 0.09 >2
18 >2 1.32 ± 0.37 0.51 ± 0.25 -0.32 ± 0.34
19 >2 >2 0.88 ± 0.49 1.21 ± 0.46
20 >2  >2  >2  0.45 ± 0.33
23 >2 >2 >2 >2
24 >2 >2 >2 >2
25 >2 >2 >2 >2
27 >2 >2 >2 >2
28 >2 >2 >2 1.63 ± 0.32
29 >2 >2  >2  >2
31 >2 >2 1.27 ± 0.58 1.92 ± 0.09
32 >2 >2 1.83 ± 0.18 1.86 ± 0.07
33 >2 >2 >2 >2
34 >2 >2  1.40 ± 0.23  1.10 ± 0.06
35 >2 >2 >2 >2
EC50 = Effective Concentration of compound resulting in 50% reduction of bacterial 
proliferation
Bacterial Proliferation log(EC50 /M) Values
SM101 
E. coli
DH5
E. coli 
MC4100  AcrB    
E. coli B. subtilis
S6 
Table S4: Inhibition results for GroEL/ES inhibitors against the ESKAPE pathogens. 
 
 
  
#
1 >2 >2 >2 >2 >2 >2 >2
5 1.96 ± 0.04 1.13 ± 0.24 0.96 ± 0.13 >2 1.76 ± 0.16 >2 >2
8 -0.82 ± 0.10 -0.69 ± 0.20 -0.88 ± 0.13 >2 1.47 ± 0.50 >2 >2
9 >2 >2 >2 >2 >2 >2 >2
10 >2  1.91 ± 0.16  >2  >2  >2  >2  >2
11 >2 1.36 ± 0.29 1.60 ± 0.30 >2 >2 >2 >2
14 >2 >2 1.97 ± 0.06 >2 >2 >2 >2
15 >2 >2 >2 >2 1.91 ± 0.11 >2 >2
18 >2 0.25 ± 0.25 0.12 ± 0.28 >2 >2 >2 >2
19 >2 1.12 ± 0.30 0.17 ± 0.31 >2 >2 >2 >2
20 >2  >2  1.33 ± 0.12  >2  >2  >2  >2
23 >2 >2 >2 >2 >2 >2 >2
24 >2 >2 1.79 ± 0.08 >2 >2 >2 >2
25 >2 >2 >2 >2 >2 >2 >2
27 >2 1.90 ± 0.08 >2 >2 >2 >2 >2
28 >2 1.65 ± 0.13 1.87 ± 0.05 >2 >2 >2 >2
29 >2  >2  1.19 ± 0.15  >2  >2  1.93 ± 0.09  >2
31 >2 >2 1.75 ± 0.20 1.98 ± 0.03 1.50 ± 0.28 >2 >2
32 1.16 ± 0.09 1.92 ± 0.13 1.73 ± 0.11 >2 >2 >2 >2
33 >2 >2 >2 >2 >2 >2 >2
34 >2  >2  >2  >2  >2  >2  >2
35 >2 >2 >2 >2 >2 >2 >2
Ampicillin -0.20 ± 0.06 -1.23 ± 0.25 1.88 ± 0.08 1.95 ± 0.01 0.41 ± 0.37 1.44 ± 0.01 >2
Minocycline <-1.3 <-1.3 -0.46 ± 0.06 -0.15 ± 0.25 <-1.3 0.38 ± 0.22 0.17 ± 0.29
Rifampicin 0.08 ± 0.13 <-1.3 -0.81 ± 0.09 0.73 ± 0.08 -0.33 ± 0.26 0.71 ± 0.15 0.79 ± 0.08
Chloramphenicol 0.32 ± 0.03 0.35 ± 0.15 0.37 ± 0.09 0.13 ± 0.12 1.81 ± 0.17 1.21 ± 0.06 0.34 ± 0.08
Kanamycin >2 0.91 ± 0.18 >2 1.65 ± 0.15 1.20 ± 0.41 1.39 ± 0.24 1.56 ± 0.06
Streptomycin 1.70 ± 0.22 0.56 ± 0.40 >2 0.53 ± 0.58 >2 0.47 ± 0.31 >2
Vancomycin -0.52 ± 0.07 -0.69 ± 0.15 -0.76 ± 0.05 >2 1.23 ± 0.18 1.87 ± 0.19 >2
Daptomycin 1.51 ± 0.01 0.76 ± 0.28 0.76 ± 0.27 >2 >2 >2 >2
EC50 = Effective Concentration of compound resulting in 50% reduction of bacterial proliferation
Bacterial Proliferation log(EC50 /M) Values ± SD
A. baumannii P. aeruginosa E. cloacaeE. faecium S. aureus K. pneumoniaeMRSA
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Table S5: Human HSP60/10 biochemical inhibition and liver and kidney cytotoxicity results for the 
GroEL/ES inhibitors.  Statistical analyses (two-tailed t-tests) were performed for compound log(IC50) 
values determined from the GroEL/ES-dMDH and HSP60/10-dMDH refolding assays.  Compounds for 
which there is a statistically significant difference between inhibition results have been marked with a 
“” between the two assay results being compared (p < 0.05).  P-values could not be calculated for 
compounds marked with a “#”as one IC50 is greater than the maximum compound concentration tested.  
IC50 correlations are represented graphically in Figure 5A in the main text. 
 
 
  
#
1 0.88 ± 0.61  1.95 ± 0.08 2.02 ± 0.16 1.47 ± 0.25 1.53 ± 0.24
5 -0.16 ± 0.35  0.69 ± 0.59 >2.4 1.20 ± 0.06 1.35 ± 0.27
8 0.15 ± 0.20  0.74 ± 0.44 0.55 ± 0.09 1.08 ± 0.09 1.89 ± 0.14
9 -0.03 ± 0.27 0.20 ± 0.22 >2.4 >2 >2
10 -0.10 ± 0.21  0.52 ± 0.04  2.15 ± 0.28  >2 >2
11 0.09 ± 0.50  0.71 ± 0.15 >2.4 0.99 ± 0.02 1.10 ± 0.10
14 0.48 ± 0.57 0.87 ± 0.15 >2.4 >2 >2
15 0.44 ± 0.52 1.01 ± 0.22 >2.4 >2 1.99 ± 0.03
18 0.76 ± 0.29 # >2 >2.4 >2 >2
19 0.68 ± 0.48 1.20 ± 0.27 >2.4 1.62 ± 0.10 1.64 ± 0.03
20 0.73 ± 0.26  0.45 ± 0.54  >2.4  0.56 ± 0.31  1.23 ± 0.48
23 0.67 ± 0.82 1.12 ± 0.15 >2.4 >2  >2
24 0.56 ± 0.45 0.91 ± 0.25 >2.4 1.53 ± 0.05  1.74 ± 0.17
25 0.81 ± 0.46 1.19 ± 0.11 >2.4 >2  >2
27 0.67 ± 0.30  1.12 ± 0.17 >2.4 >2  >2
28 0.42 ± 0.62  0.26 ± 0.31  >2.4  >2  >2
29 1.38 ± 0.07  1.58 ± 0.18 >2.4  >2  >2
31 1.49 ± 0.61 # >2 >2.4 1.17 ± 0.17 0.89 ± 0.39
32 1.62 ± 0.16 # >2 >2.4 1.78 ± 0.11 1.79 ± 0.16
33 >2 >2 >2.4 >2 >2
34 1.38 ± 0.37 1.41 ± 0.53 >2.4 >2  >2
35 >2 >2 >2.4 >2 >2
IC50 = Inhibitor Concen IC50 = Inhibitor Concentration resulting in 50% reduction of biochemical activity
EC50 = Effective ConceEC50 = Effective Concentration of compound resulting in 50% reduction in cell viability
Biochemical Assay 
log(IC50 /M) Values ± SD
Human Cell Viability Assay 
log(EC50 /M) Values ± SD
GroEL/ES-dMDH 
Refolding
HSP60/10-dMDH 
ATPase THLE-3 (Liver) HEK 293 (Kidney)
HSP60/10-dMDH 
Refolding
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Figure S1: Evaluation of bacteriostatic vs. bactericidal mechanisms of action. Compounds 8, 18, and 
vancomycin were tested at concentrations of 4x their MICs against S. aureus (ATCC 25923).  MIC 
values were determined to be 0.60 M (0.34 g/mL) for compound 8, 8.0 M (2.4 g/mL) for 
compound 18, and 1.6 M (2.3 g/mL) for vancomycin under these experimental conditions.  All 
compounds appear to be bactericidal.  Data presented are the averages of triplicate experiments. 
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General Materials and Methods.   
DH5α and BL21 (DE3) E. coli cells were purchased from New England Biolabs, and Rosetta™ 
2 (DE3) E. coli cells from EMD Millipore.  MC4100 ΔacrB E. coli cells were provided by Prof. Eli 
Chapman, University of Arizona, College of Pharmacy.  E. coli SM101 lpxA2 cells were obtained from 
the Coli Genetic Stock Center at Yale University (CGSC #7255).  B. subtilis 168 cells were provided by 
Dr. Leendert Hamoen from the University of Amsterdam, Swammerdam Institute for Life Sciences 
(SILS).  The ESKAPE pathogens were purchased from the American Type Culture Collection (ATCC): 
E. faecium (Orla-Jensen) Schleifer and Kilpper-Balz strain NCTC 7171 (ATCC 19434); S. aureus subsp. 
aureus Rosenbach strain Seattle 1945 (ATCC 25923); Methicillin-resistant S. aureus (MRSA) subsp. 
aureus Rosenbach strain HPV107 (ATCC BAA-44); K. pneumonia, subsp. pneumoniae (Schroeter) 
Trevisan strain NCTC 9633 (ATCC 13883); A. baumannii Bouvet and Grimont strain 2208 (ATCC 
19606); P. aeruginosa (Schroeter) Migula strain NCTC 10332 (ATCC 10145); E. cloacae, subsp. 
cloacae (Jordan) Hormaeche and Edwards strain CDC 442-68 (ATCC 13047).  HEK 293 kidney cells 
(ATCC CRL-1573) and THLE-3 liver cells (ATCC CRL-11233) were used for compound toxicity 
assays.  Antibiotics were used in following concentrations when appropriate; Kanamycin (34 μg/mL), 
Ampicillin (50 μg/mL), Chloramphenicol (30 μg/mL) and Streptomycin (100 μg/mL).  Test compounds 
were purchased from commercial suppliers where available (Chembridge, ChemDiv, Ambinter, Aldrich, 
Asinex, and Ryan Scientific), or synthesized according to literature procedures (compounds 10, 15, 23, 
24, and 25 – synthetic protocols are presented in the Supplementary Data below). Compounds 2-4, 6, 7, 
12, 13, 16, 17, 21, 22, 26, 30, and 36 were omitted from evaluation as they were either not commercially 
available, or purchased compounds were not readily identified by LC-MS and/or did not have acceptable 
purities confirmed by HPLC.  For ease of comparison, compound numbering from 1-36 was maintained 
as presented in our previous high-throughput screening study.1 
 
Statistical considerations. 
All IC50 (or EC50) values reported are averages of IC50 (or EC50) values determined from 
individual dose-response curves in replicate assays as follows: 1) Individual IC50 values from replicate 
assays were first log-transformed and the average log(I/EC50) values and standard deviations (SD) 
calculated; 2) Replicate log(I/EC50) values were evaluated for outliers using the ROUT method in 
GraphPad Prism 6 (Q of 10%); 3) Average IC50 (or EC50) values were then back-calculated from the 
average log(I/EC50) values.  To compare statistical differences between log(IC50) values, two-tailed, 
unpaired t-tests were performed using GraphPad Prism 6 (0.05 alpha level). 
 
Protein Expression and purification.   
E. coli GroEL was expressed from a trc-promoted plasmid in DH5α E. coli cells and purified as 
previously reported.1  E. coli GroES was expressed from a T7-promoted plasmid in E. coli BL21 (DE3) 
cells and purified as previously reported.1  Human HSP60 was expressed from a T7-promoted plasmid in 
Rosetta™ 2 (DE3) E. coli cells and purified as previously reported.2  For human HSP10 purification, 
pET30-HSP10 was transformed into Rosetta™ 2 (DE3) E. coli cells for over-expression.  Cells were 
grown at 37°C in LB/Kanamycin/Chloramphenicol medium until an OD600 of 0.5 was reached, then 
were induced with 0.5 mM IPTG and continued to grow for 2-3 h at 37°C.  The culture was centrifuged 
at 14,000 rpm, and the cell pellet was re-suspended in Buffer A (50 mM sodium acetate, pH 4.5, and 0.5 
mM EDTA), supplemented with EDTA-free complete protease inhibitor cocktail (Roche), 100 g/ml 
lysozyme, 10 µL (1000 u/ml) DNAase, and lysed by sonication.  Clarified cell lysate was loaded on a 
cation exchange column (SP Sepharose fast flow resin, GE) and eluted with linear NaCl gradient with 
Buffer B (sodium acetate, pH 4.5, 0.5 mM EDTA, and 1 M NaCl).  Fractions containing HSP10 were 
concentrated, dialyzed with storage buffer (50 mM Tris-HCl, pH 7.4, and 300 mM NaCl) using 10 kDa 
SnakeSkin™ dialysis tubing (Thermo Scientific) and re-purified on a Superdex 200 column (HiLoad 
26/600, GE) in storage buffer.  The concentration of protein was determined by Coomassie Protein 
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Assay Kit (Thermo Scientific).  Protein was stored at 4°C in 50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 
and 1 mM DTT. 
 
Evaluation of compounds in GroEL/ES and HSP60/10-mediated dMDH refolding assays. 
Reagent preparation:  For these assays, four primary reagent stocks were prepared: 1) GroEL/ES-
dMDH or HSP60/10-dMDH binary complex stock; 2) ATP initiation stock; 3) EDTA quench stock; 4) 
MDH enzymatic assay stock.  Denatured MDH (dMDH) was prepared by 2-fold dilution of MDH (5 
mg/ml, soluble pig heart MDH from Roche, product #10127248001) with denaturant buffer (7 M 
guanidine-HCl, 200 mM Tris, pH 7.4, and 50 mM DTT).  MDH was completely denatured by 
incubating at room temperature for 30 min.  The binary complex solutions were prepared by slowly 
adding the dMDH stock to a stirring stock with GroEL (or HSP60) in folding buffer (50 mM Tris-HCl, 
pH 7.4, 50 mM KCl, 10 mM MgCl2, and 1 mM DTT), followed by addition of GroES (or HSP10).  The 
binary complex stocks were prepared immediately prior to use and had final protein concentrations of 
83.3 nM GroEL (Mr 800 kDa) or HSP60 (Mr 400 kDa), 100 nM GroES or HSP10 (Mr 70 kDa), and 20 
nM dMDH in folding buffer.  For the ATP initiation stock, ATP solid was diluted into folding buffer to 
a final concentration of 2.5 mM.  Quench solution contained 600 mM EDTA (pH 8.0).  The MDH 
enzymatic assay stock consisted of 20 mM sodium mesoxalate and 2.4 mM NADH in reaction buffer 
(50 mM Tris-HCl, pH 7.4, 50 mM KCl, and 1 mM DTT). 
Assay Protocol:  First, 30 L aliquots of the GroEL/ES-dMDH or HSP60/10-dMDH binary complex 
stocks were dispensed into clear, 384-well polystyrene plates.  Next, 0.5 L of the compound stocks (10 
mM to 4.6 M, 3-fold dilutions in DMSO) were added by pin-transfer (V&P Scientific).  The 
chaperonin-mediated refolding cycles were initiated by addition of 20 L of ATP stock (reagent 
concentrations during refolding cycle: 50 nM GroEL or HSP60, 60 nM GroES or HSP10, 12 nM 
dMDH, 1 mM ATP, and compounds of 100 M to 46 nM, 3-fold dilution series). After incubation for 
60 minutes at 37°C, the assays were quenched by addition of 10 L of the EDTA to final concentration 
of 100 mM.  Enzymatic activity of the refolded MDH was initiated by addition of 20 L MDH 
enzymatic assay stock (20 mM sodium mesoxalate and 2.4 mM NADH in reaction buffer, 50 mM Tris 
pH 7.4, 50 mM KCl, 1 mM DTT), and followed by measuring the NADH absorbance in each well at 
340 nm using a Molecular Devices, SpectraMax Plus384 microplate reader (NADH absorbs at 340 nm, 
while NAD+ does not).  A340 measurements recorded at 0.5 minutes (start point) and at successive time 
points until the amount of NADH consumed reached ~90% (end point, generally between 30-60 
minutes).  The differences between the start and end point A340 values were used to calculate the % 
inhibition of the GroEL/ES or HSP60/10 machinery by the compounds.  IC50 values for the test 
compounds were obtained by plotting the % inhibition results in GraphPad Prism 6 and analyzing by 
non-linear regression using the log (inhibitor) vs. response (variable slope) equation.  Results presented 
represent the averages of IC50 values obtained from at least triplicate experiments.  
 
Counter-screening compounds for inhibition of native MDH enzymatic activity. 
Reagent Preparations & Assay Protocol:  Reagents were identical to those used in the GroEL/ES-
dMDH refolding assay described above; however, the assay protocol differed in the sequence of 
compound addition to the wells.  Compounds were pin-transferred after the EDTA quenching step, but 
prior to the addition of the enzymatic reporter reagents.  Thus, the refolding reactions were allowed to 
proceed for 60 min at 37°C in the absence of test compounds, but the enzymatic activity of the refolded 
MDH reporter enzyme was monitored in the presence of test compounds (inhibitor concentration range 
during the enzymatic reporter reaction is 83.3 µM to 38 nM – 3-fold dilutions).  IC50 values for the 
MDH reporter enzyme were determined as described above.  Results presented represent the averages of 
IC50 values obtained from at least triplicate experiments. 
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Evaluation of compounds for inhibition of chaperonin-dependent ATPase activity. 
Reagent preparation:  For these assays, four primary reagent stocks were prepared: 1) GroEL/ES-
dMDH or human HSP60/10-dMDH binary complex stock; 2) ATP initiation stock; 3) EDTA quench 
stock; 4) malachite green reporter stock.  The dMDH stock was prepared as in the above refolding 
assays.  Binary complex solutions were immediately prepared prior to use, with final concentrations of 
100 nM GroEL or HSP60, 120 nM GroES or HSP10, and 250 nM dMDH in folding buffer (50 mM 
Tris-HCl, pH 7.4, 50 mM KCl, 10 mM MgCl2, and 1 mM DTT).  For the ATP initiation stock, ATP 
solid was diluted into folding buffer to a final concentration of 2 mM.  Quench solution contained 300 
mM EDTA (pH 8.0).  The malachite green reporter stock consisted of 0.034% malachite green and 
1.04% ammonium molybdate tetrahydrate in 1 M HCl with 0.02% Tween-20. 
Assay protocol:  First, 10 L aliquots of binary stock were dispensed into clear, flat-bottom, 384-well 
polystyrene plates.  Next, 0.5 L of the compound stocks (10 mM to 4.6 M, 3-fold dilutions in DMSO) 
were added by pin-transfer.  The ATP-dependent chaperonin refolding cycles were initiated by addition 
of 10 L ATP stock (reagent concentrations during the assay; 50 nM GroEL or HSP60, 60 nM GroES or 
HSP10, 125 nM dMDH, 1 mM ATP, and compounds from 250 M to 114 nM, 3-fold dilution series).  
The reactions were incubated at 37°C for 60 minutes, then were quenched by addition of 10 L of the 
EDTA solution.  After quenching, 60 L of the malachite green reporter stock was added and incubated 
at room temperature for 15 min, then the absorption was measured at 600 nm.  A second set of baseline 
control plates were prepared analogously, but without binary solution, to correct for possible 
interference from compound absorbance or turbidity.  IC50 values for the test compounds were obtained 
by plotting the OD600 results in GraphPad Prism 6 and analyzing by non-linear regression using the 
log(inhibitor) vs. response (variable slope) equation.  Results presented represent the averages of IC50 
values obtained from at least triplicate experiments. 
 
Evaluation of compounds in GroEL/ES in denatured Rhodanese refolding assay. 
Reagent preparation:  For this assay, five primary reagent stocks were prepared: 1) GroEL/ES-dRho 
binary complex stock; 2) ATP initiation stock; 3) thiocyanate enzymatic assay stock; 4) formaldehyde 
quench stock; 5) ferric nitrate reporter stock.  Denatured Rhodanese (dRho) was prepared by 3-fold 
dilution of Rhodanese (Roche product #R1756, diluted to 10 mg/mL with H2O) with denaturant buffer 
(12 M Urea, 50 mM Tris-HCl, pH 7.4, and 10 mM DTT).  Rhodanese was completely denatured by 
incubating at room temperature for 30 min.  The binary complex solution was prepared by slowly 
adding the dRho stock to a stirring stock of concentrated GroEL in modified folding buffer (50 mM 
Tris-HCl, pH 7.4, 50 mM KCl, 10 mM MgCl2, 5 mM Na2S2O3 and 1 mM DTT).  The solution was 
centrifuged at 16,000 x g for 5 minutes, and the supernatant was collected and added to a solution of 
GroES in modified folding buffer to give final protein concentrations of 100 nM GroEL, 120 nM 
GroES, and 80 nM dRho in modified folding buffer.  The binary complex stock was prepared 
immediately prior to use.  For the ATP initiation stock, ATP solid was diluted into modified folding 
buffer to a final concentration of 2.0 mM.  The thiocyanate enzymatic assay stock was prepared to 
contain 70 mM KH2PO4, 80 mM KCN, and 80 mM Na2S2O3 in water.  The formaldehyde quench 
solution contained 30% formaldehyde in water.  The ferric nitrate reporter stock contained 8.5% w/v 
Fe(NO3)3 and 11.3% v/v HNO3 in water. 
Assay Protocol:  First, 10 L aliquots of the GroEL/ES-dRho complex stock was dispensed into clear, 
384-well polystyrene plates.  Next, 0.5 L of the compound stocks (10 mM to 4.6 M, 3-fold dilutions 
in DMSO) were added by pin-transfer.  The chaperonin-mediated refolding cycle was initiated by 
addition of 10 L of ATP stock (reagent concentrations during refolding cycle: 50 nM GroEL, 60 nM 
GroES, 40 nM dRho, 1 mM ATP, and compounds of 250 M to 114 nM, 3-fold dilution series).  After 
incubating for 60 minutes at 37°C for the refolding cycle, 30 L of the thiocyanate enzymatic assay 
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stock was added and incubated for 60 min at R.T. for the refolded Rhodenase enzymatic reporter 
reaction.  The reporter reaction was quenched by adding 10 L of the formaldehyde quench stock, and 
then 40 L of the ferric nitrate reporter stock was added to quantify the amount of thiocyanate produced 
during the enzymatic reporter reaction, which is proportional to the amount of dRho refolded by 
GroEL/ES.  After incubating at R.T. for 15 min, the absorbance by Fe(SCN)3 was measured at 460 nm 
using a Molecular Devices, SpectraMax Plus384 microplate reader.  A second set of baseline control 
plates were prepared analogously, but without binary solution, to correct for possible interference from 
compound absorbance or turbidity.  IC50 values for the test compounds were obtained by plotting the 
A460 results in GraphPad Prism 6 and analyzing by non-linear regression using the log(inhibitor) vs. 
response (variable slope) equation.  Results presented represent the averages of IC50 values obtained 
from at least triplicate experiments. 
 
Counter-screening compounds for inhibition of native Rhodanese enzymatic activity. 
Reagent Preparations & Assay Protocol:  Reagents were identical to those used in the GroEL/ES-dRho 
refolding assay described above; however, the assay protocol differed in the sequence of compound 
addition to the wells.  Compounds were pin-transferred after the incubation for 60 minutes at 37°C for 
the refolding cycle, but prior to the addition of the thiocyanate enzymatic assay stock.  Thus, the 
refolding reactions were allowed to proceed for 60 min at 37°C in the absence of test compounds, but 
the enzymatic activity of the refolded Rhodanese reporter enzyme was monitored in the presence of test 
compounds (inhibitor concentration range during the enzymatic reporter reaction is 100 M to 46 nM – 
3-fold dilutions).  IC50 values for the Rhodenase reporter enzyme were determined as described above. 
Results presented represent the averages of IC50 values obtained from at least triplicate experiments. 
 
Evaluation of compounds for inhibition of bacterial cell proliferation.   
All E.coli strains and B. subtilis 168 were grown using Luria-Bertani (LB) media broth/agar, 
unless specified otherwise.  S. aureus and MRSA were grown using ATCC Medium 18.  All other 
ESKAPE pathogens (E. faecium, K. pneumonia, A. baumannii, P. aeruginosa, and E. cloacae), were 
grown using Brain Heart Infusion media broth/agar (Becton, Dickinson and Company). 
General Assay Protocol:  Stock bacterial cultures were streaked onto agar plates and grown overnight at 
37°C.  Fresh aliquots of broth were inoculated with single bacterial colonies and the cultures were 
grown overnight at 37°C with shaking (250 rpm).  The following morning, the overnight cultures were 
sub-cultured (1:5 dilution) into fresh aliquots of media and grown at 37°C for 2 h with shaking. After 2 
h, cultures were diluted into fresh media to achieve final OD600 readings of 0.0125.  Aliquots of these 
diluted cultures (80 L) were added to clear, flat-bottom, 384-well polystyrene plates that were stamped 
with 1.0 L of test compounds in 20 L media (8x, 3-fold dilution series stocks ranging from 10 mM to 
4.6 M in DMSO).  Plates were sealed with "Breathe Easy" oxygen permeable membranes (Diversified 
Biotech) and left to incubate at 37°C without shaking (stagnant assay).  OD600 readings were taken at the 
6-8 h time points, depending on the time for each bacterial strain to reach mid-log phase growth.  A 
second set of baseline control plates were prepared analogously, but without any bacteria added, to 
correct for possible compound absorbance and/or precipitation.  EC50 values for the test compounds 
were obtained by plotting the OD600 results in GraphPad Prism 6 and analyzing by non-linear regression 
using the log(inhibitor) vs. response (variable slope) equation.  Results presented represent the averages 
of EC50 values obtained from at least triplicate experiments.  
Evaluation of compounds for inhibition of MC4100 ΔacrB E. coli cell growth:  MC4100 ΔacrB E. coli 
were streaked onto an LB agar plate containing 50 g/mL kanamycin and grown overnight at 37°C.  The 
following morning, the overnight culture was sub-cultured (1:5 dilution) into a fresh aliquot of media, 
without addition of antibiotic, and grown at 37°C for 2 h with shaking.  After 2 h, the culture was diluted 
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into fresh media to achieve a final OD600 reading of 0.0125.  All the other steps were followed 
identically as described above. 
Evaluation of compounds for inhibition of SM101 lpxA2 E. coli cell growth:3, 4   SM101 lpxA2 E. coli 
were streaked onto an LB agar plate containing 50 g/mL streptomycin and grown at 31°C.  A fresh 
aliquot of LB media (without any NaCl but with streptomycin added) was inoculated with a single 
bacterial colony and the culture was split into two, with one half grown overnight at 31°C and the other 
at 37°C (no growth control), with shaking at 250 rpm.  The following morning, the culture grown at 
31°C was diluted into fresh LB media to achieve a final OD600 reading of 0.0125 (if the culture 
incubated at 37°C grew, new cultures were prepared).  Aliquots of this diluted culture (80 L) were 
added to 384-well clear bottom polystyrene plates that had been previously stamped with 1.0 L of test 
compounds  in 20 L media (8x, 3-fold dilution series stocks ranging from 10 mM to 4.6 M in DMSO; 
compounds were added by pin transfer).  The plates were sealed with "Breathe Easy" oxygen permeable 
membranes and left to incubate at 31°C for 12 h without shaking (stagnant assay).  At the 12 h time 
point, the plates were removed and the OD600 read using a SpectraMax Plus 384 UV-Vis 
spectrophotometer to follow cell growth.  A second set of baseline control plates were prepared 
analogously, but without any bacteria added, to correct for possible compound absorbance and/or 
precipitation.  Separate control cultures were prepared from the diluted SM101 lpxA2 bacteria and 
grown at 31°C and 37°C, with shaking at 250 rpm, to verify growth in the 31°C culture and no growth in 
the 37°C culture.  If bacteria grew in the 37°C no growth control, then the assay was repeated.  EC50 
values were determined as described above.  Results presented represent the averages of EC50 values 
obtained from at least triplicate experiments. 
 
Evaluation of bacteriostatic vs. bactericidal mechanisms of action.   
Minimal inhibitory concentration (MIC) determination. 
A fresh aliquot of ATCC Medium 18 (Tryptic Soy broth) was inoculated with a single S. aureus 
(ATCC 25923) bacterial colony and the culture was grown overnight at 37°C with shaking (250 rpm).  
The following morning, the overnight culture was diluted 5-fold into fresh media and grown at 37°C for 
1 h with shaking.  After 1 h, the sub-culture was diluted to an OD600 of 0.01 (~107 CFU/ml) in fresh 
media.  200 µL aliquots were added to clear, flat-bottom, 96-well polystyrene plates.  2 µL of 
compounds 8, 18, and vancomycin in DMSO were then added to the wells (final concentrations of 
compounds were: 8 = 0.2, 0.4, 0.6, 0.8, 1.0, and 1.2 μM; 18 = 2, 4, 6, 8, 10, and 12 μM; vancomycin = 
1.2, 1.4, 1.6, 1.8, 2.0, and 2.2 μM).  The plates were then sealed with "Breathe Easy" oxygen permeable 
membranes (Diversified Biotech) and incubated at 37°C without shaking (stagnant assay) for 24 h, after 
which the MICs were identified visually (MICs: 8 = 0.6 M; 18 = 8 M; Vancomycin = 1.6 M). 
Bactericidal activity of compounds. 
A fresh aliquot of ATCC Medium 18 was inoculated with a single S. aureus (ATCC 25923) 
bacterial colony and the culture was grown overnight at 37°C with shaking (250 rpm).  The following 
morning, the overnight culture was diluted 5-fold into fresh media and grown at 37°C for 1 h with 
shaking. After 1 h, the sub-culture was diluted to optical density OD600 of 0.01 (~107 CFU/ml) in fresh 
media.  Aliquots of these diluted cultures (6 mL) were treated with DMSO (no compound control) or 4x 
MIC of compounds 8, 18, and vancomycin (60 µL of each compound stocks were added to achieve 
respective 4x MIC, final DMSO concentration in all cultures were maintained at 1%).  All cultures were 
incubated at 37°C with shaking (250 rpm) and viable cell counts were determined at 0, 1, 2, 4, 6, and 24 
h time intervals by dilution and plating on ATCC Medium 18 agar.  Time-kill curves presented in 
Figure S1 are averaged values from triplicate experiments. 
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Evaluation of compounds for cytotoxicity to HEK 293 and THLE-3 cells.   
Cell cytotoxicity assays were performed using the Alamar Blue reporter reagents as previously 
described.5, 6  HEK 293 cells were maintained in MEM medium (Corning Cellgro, 10-009 CV) 
supplemented with 10% FBS (Sigma, F2242).  THLE-3 cells were maintained in Clonetics BEBM 
medium (Lonza, CC-3171) supplemented with the BEGM bullet kit (Lonza, CC-3170) and 10% FBS.  
All assays were carried out in 384-well plates (BRAND cell culture grade plates, 781980).  Briefly, cells 
at 80% confluence were harvested and diluted in growth medium, then 50 L of the HEK 293 cells 
(15,000 cells/well) or THLE-3 cells (5,000 cells/well) were plated and incubated at 37°C with 5% CO2 
for 24 h.  Compound stocks (0.5 L of 10 mM to 4.6 M, 3-fold dilutions in DMSO) were added by 
pin-transfer and the plates were incubated for an additional 48 h at 37°C with 5% CO2.  The Alamar 
Blue reporter reagents were then added to a final concentration of 10%.  The plates were incubated for 4 
h (HEK 293) or 6 h (THLE-3), then sample fluorescence (535 nm excitation, 590 nm emission) was read 
using a Molecular Devices FlexStation II 384-well plate reader.  Cell viability was calculated as per 
vendor instructions.  EC50 values for the test compounds were obtained by plotting the % Alamar Blue 
reduction results in GraphPad Prism 6 and analyzing by non-linear regression using the log(inhibitor) vs. 
response (variable slope) equation.  Results presented represent the averages of EC50 values obtained 
from at least triplicate experiments.  
 
General Synthetic Methods. 
Test compounds were purchased from commercial suppliers where available (Chembridge, 
ChemDiv, Ambinter, Aldrich, Asinex, and Ryan Scientific), or synthesized as indicated below for 
compounds 10, 15, 23, 24, and 25.  Compounds 2-4, 6, 7, 12, 13, 16, 17, 21, 22, 26, 30, and 36 were 
omitted from evaluation as they were either not commercially available, or purchased compounds were 
not readily identified by LC-MS and/or acceptable purities confirmed by HPLC.  Reaction progress was 
monitored by thin-layer chromatography on silica gel 60 F254 coated glass plates (EM Sciences).  Flash 
chromatography was performed using a Biotage Isolera One flash chromatography system and eluting 
through Biotage KP-Sil Zip or Snap silica gel columns.  Reverse phase high performance liquid 
chromatography (RP-HPLC) was performed using a Waters 1525 binary pump, 2489 tunable UV/Vis 
detector (254 and 280 nm detection), and 2707 autosampler.  For analytical HPLC evaluation, samples 
were chromatographically separated using a Waters XSelect CSH C18 column (part number 186005282, 
130 Å pore size, 5 m particle size, 3.0x150 mm), eluting with a H2O:CH3CN gradient solvent system.  
Linear gradients were run from either 100:0, 80:20, or 60:40 A:B to 0:100 A:B (A = 95:5 H2O:CH3CN, 
0.05% TFA; B = 5:95 H2O:CH3CN, 0.05% TFA.  All test compounds were found to be >95% purity, 
with exception of the following: 14 = 85%, 19 = 79%, 20 = 92%, 27 = 94%, 28 = 78%, and 34 = 84%.  
For preparatory HPLC purification, samples were chromatographically separated using a Waters 
XSelect CSH C18 OBD prep column (part number 186005422, 130 Å pore size, 5 m particle size, 
19x150 mm) employing the above H2O:CH3CN solvent systems.  All compounds (purchased or 
synthesized) were confirmed by mass spectrometry, with data collected using an Agilent analytical LC-
MS at the IU Chemical Genomics Core Facility (CGCF).  1H-NMR spectra were recorded on either a 
Bruker 300 MHz or Bruker 500 MHz spectrometer.  Chemical shifts are reported in parts per million 
and calibrated to the d6-DMSO solvent peaks at 2.50 ppm.   
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Compound Syntheses.  
Ethyl-4-(4-hydroxy-3-nitrophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-6-carboxylate 
(37).7-9 
 
To a stirring mixture of 4-hydroxy-3-nitrobenzaldehyde (289 mg, 1.73 mmol) and ethyl-2-
aminobenzoate (0.25 mL, 1.7 mmol) in anhydrous acetonitrile (20 mL) was added TFA (0.12 mL, 1.6 
mmol), and the reaction was left to stir for 1 h at R.T. (under Ar).  Then, cyclopentadiene was added 
(0.75 mL, 18 mmol, freshly distilled from dicyclopentadiene) and the reaction was left to stir for 18 h.  
The reaction was then concentrated and flash chromatographic purification over silica (hexanes:DCM 
gradient) afforded ethyl-4-(4-hydroxy-3-nitrophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-
6-carboxylate (37) as a yellow solid (530 mg, 82%).  1H-NMR (500 MHz, d6-DMSO)  7.92 (d, J=2.2 
Hz, 1H), 7.66 (dd, J=1.1, 8.0 Hz, 1H), 7.57-7.63 (m, 2H), 7.29 (d, J=7.3 Hz, 1H), 7.15 (d, J=8.8 Hz, 
1H), 6.68 (t, J=7.7 Hz, 1H), 5.85-5.89 (m, 1H), 5.61 (d, J=5.0 Hz, 1H), 4.69 (d, J=3.5 Hz, 1H), 4.25 (q, 
J=6.9 Hz, 2H), 4.12 (d, J=9.1 Hz, 1H), 2.97-3.05 (m, 1H), 2.33-2.40 (m, 1H), 1.72-1.80 (m, 1H), 1.29 (t, 
J=7.3 Hz, 3H); LC-MS [MH]+ expected = 381.2 (C21H21N2O5), observed = 381.1; HPLC: 98% pure. 
 
4-(4-Hydroxy-3-nitrophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-6-carboxylic acid 
(10). 
 
Compound 37 (153 mg, 0.402 mmol) was stirred with LiOH•H2O (167 mg, 3.98 mmol) in 
H2O/MeOH/THF (1/1/3 mL) at 60°C.  After 1 h, the reaction was acidified with 1 M HCl and extracted 
into EtOAc.  The organics were washed with brine, dried over Na2SO4, filtered, and concentrated.  Prep-
HPLC purification afforded 4-(4-hydroxy-3-nitrophenyl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c]quinoline-6-carboxylic acid (10) as a yellow solid (119 mg, 84%).  1H-NMR (300 MHz, 
d6-DMSO)  7.86-7.963 (m, 2H), 7.64 (d, J=6.6 Hz, 2H), 7.25 (d, J=6.9 Hz, 1H), 7.19 (d, J=8.8 Hz, 
1H), 6.64 (t, J=7.6 Hz, 1H), 5.87 (br s, 1H), 5.6 (d, J=5.4 Hz, 1H), 4.69 (br s, 1H), 4.11 (d, J=9.1 Hz, 
1H), 2.95-3.05 (m, 1H), 2.33-2.41 (m, 1H); LC-MS [MH]+ expected = 353.1 (C19H17N2O5), observed = 
353.1; HPLC: >99% pure. 
 
4-(2-((4-Nitrophenyl)amino)thiazol-4-yl)benzene-1,2-diol (38).10, 11  
 
2-Chloro-3’,4’-dihydroxyacetophenone (567 mg, 3.04 mmol) and N-(4-nitrophenyl)thiourea (555 mg, 
2.81 mmol) were refluxed in ethanol (20 mL) for 4 h, then cooled on ice.  The precipitate was filtered, 
rinsed with ice cold EtOH, and dried to afford 4-(2-((4-nitrophenyl)amino)thiazol-4-yl)benzene-1,2-diol 
S16 
(38) as a yellow powder (750 mg, 81%).  1H-NMR (500 MHz, d6-DMSO)  11.04 (s, 1H), 8.25 (d, J=9 
Hz, 2H), 7.94 (d, J=9.1 Hz, 2H), 7.35 (d, J=2.2 Hz, 1H), 7.24 (dd, J=2.0, 8.0 Hz, 1H), 7.19 (s, 1H), 6.79 
(d, J=8.2 Hz, 1H); LC-MS [M-H]- expected = 328.0 (C15H10N3O4S), observed = 327.9; HPLC: 98% 
pure. 
 
4-(2-((4-Aminophenyl)amino)thiazol-4-yl)benzene-1,2-diol (15). 
 
Tin powder (884 mg, 7.45 mmol) was added portion-wise to a stirring mixture of compound 38 (721 
mg, 2.41 mmol) in 10% HCl in AcOH (11 mL) and the reaction was stirred at 100°C for 2 h, then at 
R.T. overnight.  The reaction was then diluted into 50% EtOAc in water and neutralized with solid 
NaHCO3.  The slurry was filtered and the organics collected, dried over Na2SO4, filtered, and 
concentrated.  Flash chromatographic purification over silica (hexanes:EtOAc gradient), followed by 
prep-HPLC purification afforded 4-(2-((4-aminophenyl)amino)thiazol-4-yl)benzene-1,2-diol (15) as an 
off-white solid (21.3 mg, 3%).  1H-NMR (500 MHz, d6-DMSO)  10.31 (s, 1H), 9.06 (br s, 1H), 8.92 (br 
s, 1H), 7.78 (d, J=8.8 Hz, 2H), 7.31 (d, J=1.9 Hz, 1H), 7.26 (d, J=8.2 Hz, 2H), 7.20 (dd, J=2.2, 8.2 Hz, 
1H), 7.00 (s, 1H), 6.77 (d, J=8.2 Hz, 1H); LC-MS [MH]+ expected = 300.1 (C15H14N3O2S), observed = 
300.0; HPLC: 99% pure. 
 
2,3-Di(furan-2-yl)-6-nitroquinoxaline (39).12-14 
 
1,2-Diamino-4-nitrobenzene (1.57 g, 10.3 mmol) and 2,2’-furil (1.93 g, 10.2 mmol) were refluxed 
together in EtOH (40 mL) for 4 h.  The reaction was then cooled over ice and the precipitate filtered, 
rinsed with ice-cold EtOH and hexanes, collected, and dried to afford 2,3-di(furan-2-yl)-6-
nitroquinoxaline (39) as an orange solid (2.54 g, 81%).  1H-NMR (300 MHz, d6-DMSO)  8.84 (d, J=2.2 
Hz,, 1H), 8.51 (dd, J=2.6, 9.2 Hz, 1H), 8.28 (d, J=9.2 Hz, 1H), 7.97-8.02 (m, 2H) 6.92 (dd, J=0.7, 3.4 
Hz, 1H), 6.87 (dd, J=0.7, 3.5 Hz, 1H), 6.77 (dt, J=1.6, 3.4 Hz, 2H); LC-MS [MH]+ expected = 308.1 
(C16H10N3O4), observed = 308.0; HPLC: 96% pure. 
 
2,3-Di(furan-2-yl)quinoxalin-6-amine (40). 
 
Tin powder (2.83 g, 23.8 mmol) was added portion-wise to a stirring mixture of compound 39 (2.40 g, 
7.81 mmol) in 10% HCl in AcOH (22 mL) and the reaction was stirred at R.T. overnight.  The reaction 
was then diluted into 50% EtOAc in water and neutralized with solid NaHCO3.  The slurry was filtered 
and the organics collected, dried over Na2SO4, filtered, and concentrated.  Flash chromatographic 
purification over silica (hexanes:EtOAc gradient) afforded 2,3-di(furan-2-yl)quinoxalin-6-amine (40) as 
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a brown-orange solid (996 mg, 46%).  1H-NMR (300 MHz, d6-DMSO)  7.78-7.85 (m, 2H), 7.75 (d, 
J=9.0 Hz, 1H), 7.26 (dd, J=2.4, 9.0 Hz, 1H), 6.91 (d, J=2.3 Hz, 1H), 6.64 (ddd, J=1.2, 1.8, 3.4 Hz, 2H), 
6.53 (dd, J=0.8, 3.4 Hz, 1H), 6. 50 (dd, J=0.7, 3.4 Hz, 1H), 6.29 (s, 2H); LC-MS [MH]+ expected = 
278.1 (C16H12N3O2), observed = 278.1; HPLC: 88% pure. 
 
N-(2,3-Di(furan-2-yl)quinoxalin-6-yl)pyrrolidine-1-carboxamide (23).12-14 
 
Triethylamine (0.11 mL, 0.79 mmol) was added to a stirring mixture of compound 40 (72.2 mg, 0.261 
mmol) and triphosgene (29.1 mg, 0.0981 mmol) in anhydrous DCM (5 mL), and the reaction was stirred 
for at R.T. (under Ar).  After 2 h, pyrrolidine (65.0 L, 0.79 mmol) was added and the reaction stirred 
for an additional 4 h.  Flash chromatographic purification over silica (hexanes:EtOAc gradient), 
followed by prep-HPLC purification afforded N-(2,3-di(furan-2-yl)quinoxalin-6-yl)pyrrolidine-1-
carboxamide (23) as an orange solid (34.2 mg, 93%).  1H-NMR (300 MHz, d6-DMSO)  8.72 (s, 1H), 
8.36 (d, J=2.0 Hz, 1H), 8.02 (dd, J=2.3, 9.2 Hz, 1H), 7.95 (d, J=9.0 Hz, 1H), 7.85-7.89 (m, 2H), 6.62-
6.72 (m, 4H), 3.42-3.50 (m, 4H), 1.86-1.93 (m, 4H); LC-MS [MH]+ expected = 375.2 (C21H19N4O3), 
observed = 375.1; HPLC: 98% pure. 
 
N-(4-Acetylphenyl)thiophene-2-carboxamide (41). 
 
Pyridine (0.39 mL, 4.8 mmol) was added to a stirring mixture of 2-thiophenecarbonyl chloride (0.43 
mL, 4.0 mmol) and 2-aminoacetophenone (537 mg, 3.97 mmol) in anhydrous DCM (8 mL) and the 
reaction was left to stir at R.T. (under Ar).  After 4 h, the reaction was extracted into EtOAc and the 
organics were washed with water and brine, dried over Na2SO4, filtered, and concentrated.  Flash 
chromatographic purification over silica (hexanes:EtOAc gradient) afforded N-(4-
acetylphenyl)thiophene-2-carboxamide (41) as a pale yellow solid (784 mg, 81%).  1H-NMR (300 MHz, 
d6-DMSO)  10.54 (s, 1H), 8.08 (dd, J=1.1, 3.7 Hz, 1H), 7.95-8.01 (m, 2H), 7.86-7.93 (m, 3H), 7.25 
(dd, J=3.8, 5.0 Hz, 1H), 2.55 (s, 3H); LC-MS [MH]+ expected = 246.1 (C13H12NO2S), observed = 246.0; 
HPLC: 99% pure. 
 
(E)-N-(4-(3-(Furan-2-yl)acryloyl)phenyl)thiophene-2-carboxamide (24).15, 16 
 
Compound 41 (0.145 mg, 0.591 mmol) and 2-furaldehyde (54.0 L, 0.652 mmol) were refluxed in a 
mixture of EtOH (8 mL) in 1 M NaOH (12 mL).  After 4 h, the reaction was cooled on ice and the 
precipitate filtered, rinsed with ice cold EtOH, collected, and dried.  Flash chromatographic purification 
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over silica (hexanes:EtOAc gradient) afforded (E)-N-(4-(3-(furan-2-yl)acryloyl)phenyl)thiophene-2-
carboxamide (24) as a yellow solid (140 mg, 73%).  1H-NMR (500 MHz, d6-DMSO)  10.54 (s, 1H), 
8.07-8.14 (m, 3H), 7.90-7.97 (m, 4H), 7.53-7.62 (m, 2H), 7.26 (dd, J=3.8, 5.0 Hz, 1H), 7.10 (d, J=3.5 
Hz, 1H), 6.70 (dd, J=1.7, 3.5 Hz, 1H), 3.86 (s, 3H); LC-MS [MH]+ expected = 324.1 (C18H14NO3S), 
observed = 324.0; HPLC: 96% pure. 
 
1-(2,3-Di(furan-2-yl)quinoxalin-6-yl)-3-(2-hydroxyethyl)urea (25).12-14 
 
Triethylamine (0.29 mL, 2.1 mmol) was added to a stirring mixture of compound 40 (191 mg, 0.691 
mmol) and triphosgene (88.8 mg, 0.299 mmol) in anhydrous DCM (7 mL), and the reaction was stirred 
for at R.T. (under Ar).  After 2 h, ethanolamine (0.21 mL, 3.5 mmol) was added and the reaction stirred 
for an additional 4 h.  Flash chromatographic purification over silica (hexanes:EtOAc gradient), 
followed by prep-HPLC purification, afforded 1-(2,3-di(furan-2-yl)quinoxalin-6-yl)-3-(2-
hydroxyethyl)urea (25) as a red-orange powder (74.5 mg, 68%).  1H-NMR (300 MHz, d6-DMSO)  9.26 
(s, 1H), 8.26 (d, J=2.2 Hz, 1H),  7.96 (d, J=9.1 Hz, 1H), 7.84-7.89 (m, 2H), 7.72 (dd, J=2.3, 9.1 Hz, 1H), 
6.67-6.71 (m, 2H), 6.63-6.67 (m, 2H), 6.47 (t, J=5.6 Hz, 1H), 4.81 (br s, 1H), 3.45-3.53 (m, 2H), 3.18-
3.26 (m, 2H); LC-MS [MH]+ expected = 365.1 (C19H17N4O4), observed = 365.1; HPLC: 98% pure. 
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Table S6: Compound characterization data. 
 
 
 
 
 
 
#
1
5
8
9
10    
11
14
15
18
19
20    
23
24
25
27
28    
29
31
32
33
34
35
481.1
328.1
415.1
322.8
416.1
322.1
377.1
376.0
296.1
344.0
315.1
375.2
324.1
365.1
328.0
MS Expected
533.1
344.0
566.8
363.1
351.1
284.1
335.1
300.1
322.6
416.0
322.1
377.0
375.9
481.0
343.9
315.0
375.1
324.0
365.1
415.0
C16H14N3OS2 [MH]+
533.0
343.9
566.6
363.0
351.0
284.0
335.0
300.0
296.1
C7HBr2O3S2 [M-H]- carbamate fragmented
C22H14N3O6 [M-H]-
C18H16N3O3 [MH]+
C20H17N4O4 [MH]+
C17H15BrNO4 [MH]+
C24H22FN4O4S [MH]+
C16H10NO4S2 [M-H]-
C16H12ClN2O3 [MH]+
C21H19N4O3 [MH]+
C18H13NO3S [M-H]-
C19H17N4O4 [MH]+
C20H19N2O4S2 [MH]+
97%
C27H25N4O4S2 [MH]+
C16H10NO4S2 [M-H]-
C20H10Br2ClN2O2S2 [M-H]-
C20H15N2O5 [MH]+
C19H15N2O5 [M-H]-
C15H10NO5 [M-H]-
C18H15N4O3 [MH]+
C15H14N3O2S [MH]+
C16H14N3O3 [MH]+
78%
99%
99%
99%
98%
84%
79%
92%
98%
96%
98%
94%
99%
99%
99%
99%
99%
99%
85%
99%
99%
HPLC Purity MS Formula MS Observed
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